Knight Therapeutics (TSE:GUD) Hits New 1-Year High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD)’s share price reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as C$10.76 and last traded at C$10.73, with a volume of 30407 shares traded. The stock had previously closed at C$10.54.

Knight Therapeutics Stock Performance

The firm has a market capitalization of C$1.08 billion, a P/E ratio of 73.13, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.45. The company’s 50 day moving average is C$9.91 and its 200-day moving average is C$9.06. The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. The company had revenue of C$143.97 million during the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%. As a group, equities analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.